Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 6, 2019- 11 patients enrolled to-date in Phase 1 study; combination has been generally well-tolerated -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its...
-
Nov 26, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer...
-
Nov 6, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both fimepinostat and...
-
Nov 5, 2019- Management to host conference call today at 8:30 a.m. ET -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter...
-
Oct 31, 2019
In a release issued under the same headline on October 29th by Curis, Inc., please note that in the first and second paragraphs of the release, financial results will be reported before Nasdaq...